PharmaCE- Continuing Education


Antidepressant-Induced Liver Injury

Kevin P DeSanty PharmD PhD, and Celene M Amabile PharmD BCPS

Program Information Program Information         Email to a FriendEmail to a Friend       Add to Cart Add to Cart         Continue Shopping 




OBJECTIVE: To review principles of drug-induced liver injury (DILI), summarize characteristics of antidepressant-mediated liver injury, and provide recommendations for monitoring and management.

DATA SOURCES: A search relating to antidepressant-induced liver injury was performed using MEDLINE (1966-March 2007). Search terms included antidepressant, cholestasis, hepatotoxicity, jaundice, liver injury, toxic hepatitis, and transaminases. Reference citations not identified in the initial database search were also utilized.

STUDY SELECTION AND DATA EXTRACTION: All English-language case reports, letters, and review articles identified from the data sources were used. Case reports and letters relating to hepatotoxicity from antidepressant overdose were excluded.

DATA SYNTHESIS: Antidepressant-induced liver injury described in published cases were of the idiopathic type and, by definition, cannot be predicted based on dose or specific risk factors. Paroxetine had the largest number of cases within the selective serotonin-reuptake inhibitor class. Nefazodone, a serotonin-norepinephrine reuptake inhibitor, appeared to have the most serious cases and is the only antidepressant agent that carries a Food and Drug Administration Black Box Warning regarding hepatotoxicity. The tricyclic antidepressants and monoamine oxidase inhibitors are capable of producing hepatotoxicity, but fewer cases with these agents have been reported in the past 15 years, possibly due to a decline in their use. Causality has not been well established in all reports due to the concurrent use of other drugs and/or underlying liver disease.

CONCLUSIONS: Most antidepressant agents have the potential to produce idiopathic liver injury. There is no way to prevent idiopathic DILI, but the severity of the reaction may be minimized with prompt recognition and early withdrawal of the agent. The clinician must be careful to provide ongoing therapy of the underlying depressive disorder and be aware of possible drug discontinuation syndromes should potential hepatotoxicity be suspected.

Key Words: antidepressant, hepatotoxicity, liver injury

Published Online, 3 July 2007, www.theannals.com, DOI 10.1345/aph.1K114.
The Annals of Pharmacotherapy: Vol. 41, No. 7, pp. 1201-1211.

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER:
407-000-07-019-H01


PharmaCETM
is a service of HARVEY WHITNEY BOOKS COMPANY
8044 Montgomery Road, Suite 415, Cincinnati, OH 45236-2919
P.O. Box 42696, Cincinnati, OH 45242-0696 USA
Toll Free: 877/742-7631
Tel. 513/793-3555, FAX 513/793-3600
Office Hours: Monday - Friday 9-5 E.S.T.
Contact Us
All Rights Reserved. Copyright © 1998-